CR20120503A - Inhibidores no nucleosídicos de la transcriptasa inversa - Google Patents

Inhibidores no nucleosídicos de la transcriptasa inversa

Info

Publication number
CR20120503A
CR20120503A CR20120503A CR20120503A CR20120503A CR 20120503 A CR20120503 A CR 20120503A CR 20120503 A CR20120503 A CR 20120503A CR 20120503 A CR20120503 A CR 20120503A CR 20120503 A CR20120503 A CR 20120503A
Authority
CR
Costa Rica
Prior art keywords
inhibitors
nucleosid
reverse transcript
prophylaxis
formula
Prior art date
Application number
CR20120503A
Other languages
English (en)
Spanish (es)
Inventor
Jason Burch
Bernard Cote
Natalie Nguyen
Chun Sing Li
Miguel St-Onge
Danny Gauvreau
Original Assignee
Merck Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44710363&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20120503(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Canada Inc filed Critical Merck Canada Inc
Publication of CR20120503A publication Critical patent/CR20120503A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CR20120503A 2010-03-30 2012-10-01 Inhibidores no nucleosídicos de la transcriptasa inversa CR20120503A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31882410P 2010-03-30 2010-03-30
US32157310P 2010-04-07 2010-04-07

Publications (1)

Publication Number Publication Date
CR20120503A true CR20120503A (es) 2013-01-09

Family

ID=44710363

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20120503A CR20120503A (es) 2010-03-30 2012-10-01 Inhibidores no nucleosídicos de la transcriptasa inversa

Country Status (44)

Country Link
US (2) US8486975B2 (enExample)
EP (2) EP2924034B1 (enExample)
JP (2) JP5281718B2 (enExample)
KR (1) KR101421861B1 (enExample)
CN (1) CN102971308B (enExample)
AR (1) AR080859A1 (enExample)
AU (1) AU2011235568B2 (enExample)
BR (1) BR112012024691B1 (enExample)
CA (1) CA2794377C (enExample)
CL (1) CL2012002744A1 (enExample)
CO (1) CO6630126A2 (enExample)
CR (1) CR20120503A (enExample)
CY (3) CY1118774T1 (enExample)
DK (2) DK2924034T3 (enExample)
DO (1) DOP2012000256A (enExample)
EA (1) EA024804B1 (enExample)
EC (1) ECSP12012201A (enExample)
ES (2) ES2536295T3 (enExample)
FI (1) FIC20190021I1 (enExample)
GE (1) GEP20156368B (enExample)
HN (1) HN2012002039A (enExample)
HR (2) HRP20150427T1 (enExample)
HU (4) HUE025336T2 (enExample)
IL (2) IL222030A (enExample)
LT (3) LT2924034T (enExample)
LU (2) LUC00114I2 (enExample)
MA (1) MA34170B1 (enExample)
ME (2) ME02570B (enExample)
MX (1) MX2012011379A (enExample)
MY (1) MY163979A (enExample)
NI (1) NI201200146A (enExample)
NL (1) NL300980I2 (enExample)
NO (2) NO2019019I1 (enExample)
NZ (1) NZ602670A (enExample)
PE (1) PE20130158A1 (enExample)
PH (1) PH12012501923A1 (enExample)
PL (2) PL2924034T3 (enExample)
PT (2) PT2924034T (enExample)
RS (2) RS55505B1 (enExample)
SG (1) SG184347A1 (enExample)
SI (2) SI2552902T1 (enExample)
TN (1) TN2012000455A1 (enExample)
TW (1) TWI458719B (enExample)
WO (1) WO2011120133A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2924034T (pt) * 2010-03-30 2017-01-06 Merck Canada Inc Composição farmacêutica compreendendo um inibidor de transcritase reversa não nucleosídico
US20140031250A1 (en) 2010-10-07 2014-01-30 David Tsai Ting Biomarkers of Cancer
CN109384765A (zh) * 2012-09-26 2019-02-26 默沙东公司 逆转录酶抑制剂的晶型
JO3470B1 (ar) * 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
CA2892919A1 (en) * 2012-12-05 2014-06-12 Merck Sharp & Dohme Corp. Process for making reverse transcriptase inhibitors
WO2015077273A1 (en) * 2013-11-22 2015-05-28 Merck Sharp & Dohme Corp. Composition of a non-nucleoside reverse transcriptase inhibitor
KR101803671B1 (ko) * 2013-12-04 2017-11-30 머크 샤프 앤드 돔 코포레이션 역전사효소 억제제의 제조 방법
CA2944187C (en) * 2014-04-01 2018-06-19 Merck Sharp & Dohme Corp. Prodrugs of hiv reverse transcriptase inhibitors
WO2015200697A1 (en) 2014-06-25 2015-12-30 The General Hospital Corporation Targeting human satellite ii (hsatii)
HUE056978T2 (hu) 2015-12-02 2022-04-28 Merck Sharp & Dohme Doravirint, tenofovir-dizoproxil-fumarátot és lamivudint tartalmazó gyógyszerészeti kompozíciók
WO2018175271A1 (en) * 2017-03-24 2018-09-27 Merck Sharp & Dohme Corp. Formulation for parenteral administration
CA3060222A1 (en) 2017-04-18 2018-10-25 Cipla Limited Combination therapy for use in treating retroviral infections
JP2021512956A (ja) 2018-02-06 2021-05-20 ザ ジェネラル ホスピタル コーポレイション 腫瘍免疫応答のバイオマーカーとしてのリピートrna
US12005072B2 (en) 2018-07-17 2024-06-11 Merck Sharp & Dohme Llc HIV drug combination for increasing barrier against resistance
EA202191711A1 (ru) 2018-12-18 2021-10-04 Мерк Шарп И Доум Корп. Производные пиримидона в качестве селективных цитотоксических агентов против вич-инфицированных клеток
CN110801455B (zh) * 2019-11-12 2020-06-02 河北医科大学第二医院 用于治疗mrsa的药物组合物及其应用
CN114163309B (zh) * 2021-12-27 2023-04-25 甘肃皓天医药科技有限责任公司 一种多拉韦林中间体的制备方法
CN114349690B (zh) * 2022-02-15 2023-04-25 甘肃皓天医药科技有限责任公司 一种多拉韦林中间体合成方法
CN116903590A (zh) * 2023-06-06 2023-10-20 延边大学 一种含杂环结构的吡啶酮类化合物及其制备方法和用途
CN120157613A (zh) * 2023-12-15 2025-06-17 山东诚创蓝海医药科技有限公司 多拉韦林中间体及其应用和合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904045D0 (sv) 1999-11-09 1999-11-09 Astra Ab Compounds
TW200423930A (en) 2003-02-18 2004-11-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitors
CA2518823A1 (en) 2003-03-24 2004-10-07 F.Hoffmann-La Roche Ag Benzyl-pyridazinons as reverse transcriptase inhibitors
TW200505441A (en) * 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ
ES2333802T3 (es) 2004-04-23 2010-03-01 F. Hoffmann-La Roche Ag Inhibidores no nucleicos de transcriptasa inversa.
US7166738B2 (en) 2004-04-23 2007-01-23 Roche Palo Alto Llc Non-nucleoside reverse transcriptase inhibitors
JP2008525419A (ja) 2004-12-22 2008-07-17 ファイザー・リミテッド Hiv−1逆転写酵素の非ヌクレオシド阻害剤
AR057455A1 (es) 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
JP2009515826A (ja) 2005-10-19 2009-04-16 エフ.ホフマン−ラ ロシュ アーゲー フェニル−アセトアミドnnrt阻害剤
EP1940782B1 (en) 2005-10-19 2009-03-11 F.Hoffmann-La Roche Ag N-phenyl phenylacetamide non-nucleoside reverse transcriptase inhibitors
TW200831085A (en) 2006-12-13 2008-08-01 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors
EP2222661B1 (en) 2007-11-20 2016-04-20 Merck Sharp & Dohme Corp. Non-nucleoside reverse transcriptase inhibitors
PT2924034T (pt) * 2010-03-30 2017-01-06 Merck Canada Inc Composição farmacêutica compreendendo um inibidor de transcritase reversa não nucleosídico

Also Published As

Publication number Publication date
LTPA2019506I1 (lt) 2019-04-25
LTPA2019507I1 (lt) 2019-04-25
PH12012501923A1 (en) 2013-02-04
CY2019026I1 (el) 2020-05-29
TW201139409A (en) 2011-11-16
CY2019025I2 (el) 2019-11-27
PT2552902E (pt) 2015-06-02
LT2924034T (lt) 2016-12-27
ME02570B (me) 2017-06-20
LTC2552902I2 (lt) 2019-12-10
HUS1900021I1 (hu) 2019-05-28
HN2012002039A (es) 2015-08-24
EA201290976A1 (ru) 2013-03-29
DK2924034T3 (en) 2017-02-06
MY163979A (en) 2017-11-15
NO2019019I1 (no) 2019-04-24
AR080859A1 (es) 2012-05-16
WO2011120133A1 (en) 2011-10-06
HK1209121A1 (en) 2016-03-24
KR20120128703A (ko) 2012-11-27
ECSP12012201A (es) 2012-10-30
CN102971308A (zh) 2013-03-13
HUS1900022I1 (hu) 2019-05-28
RS54017B1 (sr) 2015-10-30
JP2013510800A (ja) 2013-03-28
DOP2012000256A (es) 2012-12-15
KR101421861B1 (ko) 2014-07-22
NI201200146A (es) 2013-03-18
CY2019025I1 (el) 2019-11-27
IL233334A0 (en) 2014-09-01
SI2552902T1 (sl) 2015-10-30
CN102971308B (zh) 2015-02-04
LUC00114I1 (enExample) 2019-04-17
LUC00113I2 (enExample) 2024-05-22
BR112012024691B1 (pt) 2020-11-17
EP2552902A4 (en) 2013-09-04
FIC20190021I1 (fi) 2019-04-17
MA34170B1 (fr) 2013-04-03
US20110245296A1 (en) 2011-10-06
SI2924034T1 (sl) 2017-05-31
HUE031785T2 (en) 2017-08-28
LUC00114I2 (enExample) 2020-07-10
HUE025336T2 (en) 2016-03-29
EP2924034A1 (en) 2015-09-30
TWI458719B (zh) 2014-11-01
SG184347A1 (en) 2012-11-29
PL2924034T3 (pl) 2017-07-31
CA2794377A1 (en) 2011-10-06
RS55505B1 (sr) 2017-05-31
CL2012002744A1 (es) 2012-12-14
JP5886790B2 (ja) 2016-03-16
ME02181B (me) 2015-10-20
ES2609636T3 (es) 2017-04-21
LUC00113I9 (enExample) 2024-06-07
IL233334A (en) 2015-09-24
EA024804B1 (ru) 2016-10-31
NO2019018I1 (no) 2019-04-24
IL222030A (en) 2014-07-31
EP2552902A1 (en) 2013-02-06
EP2552902B1 (en) 2015-03-11
NZ602670A (en) 2014-09-26
US20130296382A1 (en) 2013-11-07
PE20130158A1 (es) 2013-02-28
PT2924034T (pt) 2017-01-06
PL2552902T3 (pl) 2015-10-30
JP2013209405A (ja) 2013-10-10
HRP20161680T1 (hr) 2017-01-27
NL300980I2 (nl) 2021-06-17
US8486975B2 (en) 2013-07-16
CA2794377C (en) 2015-06-16
ES2536295T3 (es) 2015-05-22
LTC2924034I2 (lt) 2020-10-12
CY2019026I2 (el) 2020-05-29
TN2012000455A1 (en) 2014-01-30
CO6630126A2 (es) 2013-03-01
JP5281718B2 (ja) 2013-09-04
HRP20150427T1 (hr) 2015-07-03
BR112012024691A2 (pt) 2019-07-02
EP2924034B1 (en) 2016-11-02
DK2552902T3 (en) 2015-06-15
AU2011235568B2 (en) 2013-09-12
NL300980I1 (nl) 2019-04-24
MX2012011379A (es) 2012-11-30
HK1175471A1 (en) 2013-07-05
CY1118774T1 (el) 2017-07-12
AU2011235568A1 (en) 2012-11-01
GEP20156368B (en) 2015-09-25

Similar Documents

Publication Publication Date Title
CR20120503A (es) Inhibidores no nucleosídicos de la transcriptasa inversa
CR20150183A (es) Derivados de 5-fenoxi-3h-pirimidin-4-ona y su uso como inhibidores de la transcriptasa inversa del vih
AR130699A2 (es) Inhibidores de la transcriptasa inversa de nucleósidos sustituidos en 4’
ECSP099373A (es) Inhibidores de transcriptasa inversa no nucleosídicos
CL2018000351A1 (es) Compuestos antivirales de fosfodiamida de éster de beta-aminoácido
MX2022002581A (es) Compuestos de benzimidazol como inhibidores de c-kit.
MX2019007585A (es) Profarmacos de ester alifatico antiviricos de tenofovir.
CR20110184A (es) Inhibidores de la integrasa del vih
BR112016022722A2 (pt) pró-fármacos de inibidores da transcriptase reversa de hiv
DOP2006000176A (es) Inhibidores de la transcriptasa reversa de vih
ECSP088126A (es) Inhibidores de la transcriptasa reversa de vih